Drug Prices Unaffected By Senate Supply Chain, Compounding Bill, CBO Indicates
This article was originally published in The Pink Sheet Daily
Executive Summary
No mention of affects to Medicare, Medicaid in the CBO score for the Senate compounding and supply chain bill, but FDA is likely to need more budget authority given that expected user fee revenues are not expected to cover the full costs of the new programs.